biostudies-literatureUnknown10(12)Turinetto M<h4>Introduction</h4>The introduction of poly (ADP-ribose) polymerase inhibitors (PARPi) in ovarian cancer has raised increasing concerns about PARPi-related myeloid neoplasms (PrMN). Therapy-related neoplasms, including myelodysplastic syndromes and acute myeloid leukemia, account for 10%-20% of cases. Expanding PARPi indications, longer survival, and aging populations may contribute to rising PrMN incidence. Randomized clinical trials and real-world analyses show a significant risk increase, but data on individual PARPi, treatment lines, and prior therapies are limited.<h4>Methods</h4>We evaluated PrMN incidence across 17 Italian centers using a 71-item survey distributed to MITO (Multicenter Italian Trials on Ovarian cancer) and MaNGO (Mario Negri Gynecologic Oncology) centers, focusingESMO open105903https://www.ebi.ac.uk/biostudies/studies/S-EPMC12670540biostudies-literaturePARPi and myeloid neoplasms; the Italian MITO-MaNGO experience based on a multicentric survey.PMC12670540Fagotti AMarchetti CCoppola EAbeni CLombardo VDeStefanis MValabrega GScandurra GGiordano MPellegrini DCamnasio CDistefano MPetrella MCCaruso GBarberi VCirigliano GPerri MTPignata SFerrero AChiusolo PCormio GBoccia SCecere SLoizzi VDe Angelis CTurinetto MColombo NVilla FMammoliti SLamia MRfalsePARPi and myeloid neoplasms; the Italian MITO-MaNGO experience based on a multicentric survey.<h4>Introduction</h4>The introduction of poly (ADP-ribose) polymerase inhibitors (PARPi) in ovarian cancer has raised increasing concerns about PARPi-related myeloid neoplasms (PrMN). Therapy-related neoplasms, including myelodysplastic syndromes and acute myeloid leukemia, account for 10%-20% of cases. Expanding PARPi indications, longer survival, and aging populations may contribute to rising PrMN incidence. Randomized clinical trials and real-world analyses show a significant risk increase, but data on individual PARPi, treatment lines, and prior therapies are limited.<h4>Methods</h4>We evaluated PrMN incidence across 17 Italian centers using a 71-item survey distributed to MITO (Multicenter Italian Trials on Ovarian cancer) and MaNGO (Mario Negri Gynecologic Oncology) centers, focusing2025-01-01T00:00:00Z2025 Dec2026-06-12T04:51:08.095Z2026-06-12T03:08:06.085ZS-EPMC126705404125990010.1016/j.esmoop.2025.105903